Submit Phase IV CT protocol: CDSCO Panel tells Roche over Anti-Cancer drug Pralsetinib
Advertisement
New Delhi: Reiterating the earlier recommendation regarding the condition of conduct a Phase IV clinical trial of anti-neoplastic drug Pralsetinib, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major Roche to submit the Phase IV clinical trial protocol of the anti-neoplastic drug Pralsetinib.
This came after the firm was granted permission to import and market Pralsetinib Capsules 100mg subject to the condition that firm should conduct a Phase IV clinical trial for which protocol should be submitted within 3 months of approval of the drug for review by the committee.
However, the expert panel observed that the firm presented its request for consideration of an alternative approach to Phase IV clinical trial.
Pralsetinib is a RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. Pralsetinib is indicated for treating metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA-approved test.
It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic RET-mutant medullary thyroid cancer, and in this same population for the treatment of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and for whom radioactive iodine is not appropriate.
Pralsetinib is a RET receptor tyrosine kinase inhibitor for the treatment of metastatic RET-driven non-small cell lung cancer. RET is an abbreviation for "rearranged during transfection", as the DNA sequence of this gene was originally found to be rearranged within a 3T3 fibroblast cell line following its transfection with DNA taken from human lymphoma cells. The human gene RET is localized to chromosome 10. Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. It constitutes extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development. Constitutive RET activation further leads to elevated downstream signalling and is associated with tumour invasion, migration, and proliferation.
At recent SEC meeting for Oncology & Haematology, the expert panel reviewed the firm's request for consideration of an alternative approach to Phase IV clinical trial of the anti-neoplastic drug Pralsetinib.
The committee noted that the firm proposed the following alternative approach to Phase IV CT:
1. The participation of Indian centres in 5 Phase III global clinical trials would include 61 Indian patients.
2. The voluntary conduct of Real World Evidence Basket study for tumour and rare condition (TARC) in 40 patients.
After detailed deliberation, the committee reiterated its earlier recommendation and stated,
'The firm should submit Phase IV clinical trial protocol before the committee."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.